C
Context Therapeutics D
D
CNTX
1.50000
USD
0.03
(1.69%)
Market Closed
Volume
2,463
EPS
-1
Div Yield
-
P/E
-2
Market Cap
112,497,468
Novo Nordisk Surges in Profit and Sales
6 months ago
Stocks news More
Title: Context Therapeutics
Sector: Healthcare
Industry: Biotechnology
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.